Management ChangeJun 22, 2026, 04:11 PM
Dyne Therapeutics Appoints Barry Greene to Board of Directors
AI Summary
Dyne Therapeutics, Inc. announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings over three decades of biopharmaceutical industry experience, including leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals, with a strong track record in commercialization and scaling innovative companies. This strategic addition aims to strengthen the board as Dyne approaches a planned transformation into a commercial biotechnology company, anticipating potential product launches and revenue generation.
Key Highlights
- Dyne Therapeutics appointed Barry Greene to its Board of Directors.
- Mr. Greene brings over three decades of biopharmaceutical industry experience.
- He has a track record of building and scaling companies from development through commercialization.
- He previously served as CEO of Sage Therapeutics and President & COO of Alnylam Pharmaceuticals.
- The appointment strengthens the board as Dyne anticipates becoming a commercial biotechnology company.
- Mr. Greene currently serves as lead independent director of Karyopharm Therapeutics.
Price Impact
More from DYN